<iframe src="//www.googletagmanager.com/ns.html?id=GTM-K799DP4&l=dataLayer" height="0" width="0" style="display:none;visibility:hidden"></iframe>
NAS:BMRN (USA) Also Trade In: Austria Germany UK

Biomarin Pharmaceutical Inc $ 67.73 0 (-1.01%)

On watch
Volume:
1,585,185
Avg Vol (1m):
1,246,420
Market Cap $:
12.16 Bil
Enterprise Value $:
12.27 Bil
P/E (TTM):
0.00
P/B:
4.09
Warning! GuruFocus has detected 2 Severe warning signs with BMRN. Click here to check it out.
5D 3M YTD 1Y 5Y 10Y All 1Y (-%)

BMRN News and Headlines - Biomarin Pharmaceutical

GuruFocus Articles Total 114
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6

Investment company CMH Wealth Management LLC (Current Portfolio) buys SPDR Portfolio S&P 500 Growth ETF, Target Corp, Bristol-Myers Squibb Company, Alphabet Inc, Biomarin Pharmaceutical Inc, sells Caterpillar Inc, UnitedHealth Group Inc, Marathon Petroleum Corp during the 3-months ended 2019Q3, according to the most recent filings of the investment company, CMH Wealth Management LLC. As of 2019Q3, CMH Wealth Management LLC owns 49 stocks with a total value of $157 million. These are the details of the buys and sells.
0 Views    [email protected]    2019-10-11 19:38

PR Newswire

SAN RAFAEL, Calif., Oct. 9, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, October 23, at 4:30 p.m. ET to discuss third quarter 2019 financial results and provide a general business update.

0 Views    PRNewswire    2019-10-09 16:00

PR Newswire

SAN RAFAEL, Calif., Oct. 7, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced the promotion of Lon Cardon, Ph.D. to Chief Scientific Strategy Officer, a newly created role to enrich BioMarin's pipeline, which drives the future growth of the company. Dr. Cardon's promotion to lead BioMarin's scientific strategy is effective immediately.

0 Views    PRNewswire    2019-10-07 16:01

PR Newswire

SAN RAFAEL, Calif., Oct. 1, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Robert Baffi, Ph.D., President of Global Manufacturing and Technical Operations, will participate in a fireside discussion at the Jefferies Gene Therapy/Editing Summit on October 8, 2019 at 11:15am ET in New York.  Dr. Baffi will also participate in the panel discussion on manufacturing, dose, and durability in gene therapy at 10:20am

0 Views    PRNewswire    2019-10-01 16:02
Altria Group Inc. (MO), BioMarin Pharmaceutical Inc. (BMRN), Pennant Park Investment Corp. (PNNT), and Rigel Pharmaceuticals Inc. (RIGL) have declined to their three-year lows

Altria Group Inc. (MO), BioMarin Pharmaceutical Inc. (BMRN), Pennant Park Investment Corp. (PNNT), and Rigel Pharmaceuticals Inc. (RIGL) have declined to their three-year lows.

Altria Group Inc. (MO) declined to $42.01

The prices of Altria Group Inc. (MO) shares have declined to $42.01 on Sept. 13, which is only 0.1% above the 3-year low of $41.97.

Altria Group Inc. is an American international tobacco corporation. The company is one of the world’s largest producers and marketers of cigarettes and other tobacco products. The company is the parent company of several companies, including Smokeless Tobacco Company Inc. and John Middleton Inc.

131 Views    Shuda Xia    2019-09-15 18:28

PR Newswire

SAN RAFAEL, Calif., Sept. 9, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Dan Spiegelman, Executive Vice President and Chief Financial Officer and Henry Fuchs, M.D., President, Worldwide Research & Development, will present at the Morgan Stanley 17th Annual Global Healthcare Conference on September 10, 2019 at 8:35am ET in New York.  To access the live webcast, please visit the investor section of the BioMarin

0 Views    PRNewswire    2019-09-10 00:00

PR Newswire

SAN RAFAEL, Calif., Aug. 28, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Dan Spiegelman, Executive Vice President and Chief Financial Officer, will present at the Morgan Stanley 17th Annual Global Healthcare Conference on September 10, 2019 at 8:35am ET in New York.  To access the live webcast, please visit the investor section of the BioMarin website, www.biomarin.com. A replay will also be archived on

0 Views    PRNewswire    2019-08-28 16:01
Concho Resources makes the list

While gurus hold positions in these companies, the share prices and returns continue to fall. As of Thursday, the following are the worst-performing stocks over the past six months with a long-term presence in more than five gurus' portfolios.

Shares of Waters Corp. (WAT) declined 9.89% over the last six months. The stock is held by eight gurus.

e76cd5b928aedff7beef51082444427e.png

The supplier of analytical instruments has a $14 billion market cap. The stock is trading with a price-book ratio of 27.57. The share price of $212 is 17.58% below the 52-week high and

103 Views    Tiziano Frateschi    2019-08-08 19:29

PR Newswire

SAN RAFAEL, Calif., July 16, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, August 1, at 4:30 p.m. ET to discuss second quarter 2019 financial results and provide a general business update.

0 Views    PRNewswire    2019-07-16 16:18

PR Newswire

SAN RAFAEL, Calif., July 9, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in providing therapies for rare genetic diseases, today announced the appointment of pharmaceutical veteran and former Johnson & Johnson executive, Liz McKee Anderson, to its Board of Directors effective July 15th, 2019.  Ms. Anderson serves on the boards of a number of life sciences companies.  Before retiring, Ms. Anderson spent 11 years in executive

0 Views    PRNewswire    2019-07-09 16:10

Potential 1st Marketing Application for a Gene Therapy Product in Any Type of Hemophilia to be Reviewed by Health Authorities

Late-Breaking Abstract at the 27th International Society on Thrombosis and Haemostasis (ISTH) 2019 Congress Presents 3 Years of Efficacy and Safety of Valoctocogene Roxaparvovec

PR Newswire

SAN RAFAEL, Calif., July 8, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that based on recent meetings with health authorities in the

0 Views    PRNewswire    2019-07-08 12:02
The newly public company develops therapies for genetic diseases

Guru Andreas Halvorsen (Trades, Portfolio), leader of Viking Global Investors, disclosed a stake in BridgeBio Pharma Inc. (BBIO) on Monday, adding to his health care holdings.

A former student of Tiger Management’s Julian Robertson (Trades, Portfolio), the investor’s Connecticut-based firm picks stocks based on its understanding of the business’ fundamentals and management team as well as cyclical and secular industry trends.

According to GuruFocus Real-Time Picks, a Premium feature, Halvorsen had invested in 26.6 million shares of the Palo Alto, California-based biopharmaceutical company as of June 27, dedicating approximately 4.04% of the equity

185 Views    Sydnee Gatewood    2019-07-02 16:48

Abstract Covers Efficacy and Safety of AAV Gene Therapy Over 3 Years with Valoctocogene Roxaparvovec in Severe Hemophilia A

PR Newswire

SAN RAFAEL, Calif., June 26, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that Professor John Pasi, M.B., Ch.B., Ph.D., from Barts and the London School of Medicine and Dentistry and principal investigator for the valoctocogene roxaparvovec Phase 1/2 study (BMN 270-201) and the Phase 3 study (BMN 270-301)

0 Views    PRNewswire    2019-06-26 16:04

European Commission Approval Triggers $15 Million Payment

BioMarin Entitled to Earn Mid-Single Digit Royalties on Future Sales

PR Newswire

SAN RAFAEL, Calif., June 21, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the Company earned a $15 million milestone payment from Pfizer, Inc.  This milestone payment was triggered by the European Commission (EC) approval of TALZENNA® (talazoparib) as monotherapy for the treatment of adult patients with germline breast

0 Views    PRNewswire    2019-06-21 16:01

Company Announces Enrollment Met for 2-5 Year-Old Cohort in Separate Phase 2 Study in Infants and Young Children

PR Newswire

SAN RAFAEL, Calif., June 18, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced that the New England Journal of Medicine (NEJM) published online today results from a Phase 2 dose-finding and extension study for vosoritide, an investigational analog of C-type Natriuretic Peptide (CNP), in children with achondroplasia. The data demonstrated that vosoritide was

0 Views    PRNewswire    2019-06-18 16:03

PR Newswire

SAN RAFAEL, Calif., June 5, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Henry Fuchs, M.D., President, Worldwide Research & Development, will present at the Goldman Sachs 40th Annual Global Healthcare Conference on Tuesday, June 11 at 8:40am PT/11:40am ET in Rancho Palos Verdes, California.  To access the live webcast, please visit the investor section of the BioMarin website, www.biomarin.com. A replay

0 Views    PRNewswire    2019-06-05 16:02

First and Only Treatment in China Approved for Patients with This Ultra-Rare Genetic Condition

More than 1,300 Patients Treated with Vimizim in Over 50 Countries

PR Newswire

SAN RAFAEL, Calif., June 4, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that Vimizim® (elosulfase alfa) has been approved by the National Medical Products Administration (NMPA) for the treatment of patients with mucopolysaccharidosis type IVA (MPS IVA), also known as Morquio A

0 Views    PRNewswire    2019-06-04 16:05

Timing of Regulatory Submissions to Be Determined in 3Q 2019

Conference Call and Webcast to be Held Tuesday, May 28, 2019 at 8:00 AM Eastern

PR Newswire

SAN RAFAEL, Calif., May 28, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that its investigational gene therapy, valoctocogene roxaparvovec, for adults with severe hemophilia A achieved pre-specified clinical criteria for regulatory review in the U.S. and Europe.  As of

0 Views    PRNewswire    2019-05-28 12:02

Substantial Reduction in excess of 92% in Mean Bleed Rate Requiring Factor VIII Infusions; Sustained over the Period of Observation (3 Years in High Dose and 2 Years in Low Dose)

Rate of FVIII Change Continued to be Expression Level Dependent, Slowed in Year 3, and Appears to be Approaching Plateau

Conference Call and Webcast to be Held Tuesday, May 28, 2019 at 8:00 AM Eastern

PR Newswire

SAN RAFAEL, Calif.,

0 Views    PRNewswire    2019-05-28 12:01

PR Newswire

SAN RAFAEL, Calif., May 27, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that management will host a conference call and webcast on Tuesday, May 28 at 8:00am ET to discuss program updates. 

BioMarin Pharmaceutical logo (PRNewsfoto/BioMarin Pharmaceutical Inc.)

Conference Call and Webcast Information 
Interested parties may access the live video webcast that will include audio

0 Views    PRNewswire    2019-05-28 00:00

Headlines Total 275
  • 1
  • 2
  • 3

2019-10-22 $ 67.73 (-1.01%)
10:32am
2019-10-17 $ 67.9 (-0.06%)
10:24am
2019-10-16 $ 67.94 (-0.83%)
9:33am
2019-09-13 $ 72.65 (-0.21%)
11:58am
2019-08-31
8:31am
2019-08-08 $ 76.89 (0.26%)
9:33am
2019-08-06 $ 76.01 (-0.01%)
10:45am
2019-08-02 $ 77.84 (-3.9%)
9:52am
1:43am
2019-08-01 $ 81 (2.12%)
5:05pm
2019-07-29 $ 79.82 (-1.59%)
8:08am
2019-07-25 $ 80.67 (-0.53%)
9:34am
2019-07-09 $ 83.13 (3.41%)
4:10pm
4:04pm
9:40am
6:00am
2019-07-08 $ 80.39 (-1.96%)
11:10am
8:55am
2019-07-03 $ 84.15 (0.12%)
8:38pm
2019-06-24 $ 85.9 (-2.29%)
10:04am
7:33am
2019-06-09
12:09pm
2019-06-06 $ 80.49 (-3.71%)
9:33am
2019-05-29 $ 82.95 (-1.83%)
9:52am
9:22am
2019-05-28 $ 84.5 (-5.13%)
7:46pm
5:00pm
2019-05-26
9:00am
2019-05-16 $ 89.67 (2.88%)
7:42am
2019-05-09 $ 83.38 (0.8%)
10:05am
2019-05-01 $ 84.18 (-1.58%)
2:29pm
2019-04-27
3:36pm
2019-04-26 $ 85.09 (-0.26%)
1:04pm
3:31am
2019-04-18 $ 83.16 (0.98%)
9:33am
2019-04-16 $ 88.51 (-3.64%)
9:51am
2019-04-10 $ 92.3 (1.08%)
11:01am
2019-04-03 $ 91.89 (0.72%)
8:13am
2019-03-29 $ 88.83 (1.16%)
10:15am
8:06am
2019-03-27 $ 87.94 (-1.92%)
9:03am
2019-03-25 $ 88.55 (0.57%)
10:10am
2019-03-23
8:30am
2019-03-19 $ 91.44 (-2.06%)
7:26pm
2019-03-18 $ 93.36 (-1.24%)
9:47am
2019-03-07 $ 91.31 (0.29%)
6:50am
2019-02-28 $ 93.26 (-0.54%)
9:54am
2019-02-22 $ 87.87 (-1.06%)
8:23am
1:39am
2019-02-14 $ 93.47 (-1.87%)
9:31am
2019-01-07 $ 90.19 (3.55%)
12:45pm
2018-12-17 $ 92.45 (-0.71%)
6:38am
2018-12-10 $ 93.83 (1.22%)
6:58am
2018-12-07 $ 92.7 (-2.97%)
7:01am
2018-12-06 $ 95.54 (1.97%)
8:20am
2018-11-23 $ 93.78 (0.2%)
8:03am
2018-11-20 $ 91.47 (-2.39%)
4:32pm
2018-11-12 $ 93.07 (-2.72%)
2:26pm
2018-11-04
6:31am
2018-11-03
9:26am
2018-10-29 $ 93.76 (-3.78%)
3:53pm
2018-10-26 $ 97.44 (1.05%)
12:05pm
3:33am
2018-10-25 $ 96.43 (3.82%)
10:06am
2018-10-18 $ 103.82 (-2.12%)
9:07am
2018-09-07 $ 98.04 (1.96%)
7:32am
2018-08-14 $ 103.14 (0.41%)
10:36am
2018-08-13 $ 102.72 (1.24%)
8:00am
2018-08-09 $ 102.03 (-1.25%)
5:11pm
10:45am
2018-08-08 $ 103.32 (-2.27%)
7:53am
6:02am
2018-08-03 $ 99.47 (-2.53%)
10:05am
2:17am
2018-08-02 $ 102.05 (1.07%)
5:00pm
2018-08-01 $ 100.97 (0.41%)
9:48am
2018-07-30 $ 99.38 (-0.66%)
9:48am
2018-07-17 $ 103.92 (1.16%)
9:11pm
2:15pm
2018-07-09 $ 99.55 (1.32%)
5:23pm
2018-07-05 $ 95.5 (1.1%)
9:32am
2018-06-18 $ 95.58 (-2.07%)
7:46am
2018-06-15 $ 97.6 (8.47%)
9:52am
2018-06-12 $ 90 (0.23%)
9:04am
2018-06-09
8:00am
2018-06-05 $ 92.13 (0.07%)
9:10am
2018-05-31 $ 90.34 (-0.29%)
3:56pm
7:04am
2018-05-30 $ 90.6 (0.07%)
9:39am
7:26am
2018-05-29 $ 90.54 (-2.11%)
9:09am
2:50am
2018-05-28 $ 92.49 (%)
6:38am
2018-05-27
7:15pm
2018-05-25 $ 92.49 (4.77%)
1:58pm
12:21pm
9:57am
7:08am
2018-05-23 $ 88.46 (0.97%)
6:00pm
2:11pm
Total 275
  • 1
  • 2
  • 3